Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Halozyme's AACR abstracts:

http://www.abstractsonline.com/pp8/#!/4562

Hyaluronan (HA) accumulation restricts CD8+ T cell numbers and skews tumor-associated macrophage (TAM) phenotype in mouse syngeneic pancreatic tumors. Abstract 1747. Monday, April 16, 8 a.m. to noon CT

PEGylated recombinant hyaluronidase PH20 (pegvorhyaluronidase alfa; PEGPH20) converts HA-rich tumors from resistant to sensitive to anti-PD-L1 immunotherapy in murine syngeneic breast cancer models. Abstract 2740. Monday, April 16, 8 a.m. to noon CT

PEGylated Adenosine Deaminase (ADA2) Prevents Adenosine-Mediated Increase in Tumor Growth and Improves Anti-Tumor Immune Responses. Abstract 1755. Monday, April 16, 8 a.m. to noon CT

Rationale for evaluating PEGylated recombinant human hyaluronidase PH20 (pegvorhyaluronidase alfa; PEGPH20) in patients with hyaluronan (HA)-accumulating colorectal cancer. Abstract 1743. Monday, April 16, 1 to 5 p.m. CT

The growth of xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44. Abstract 2101. Monday, April 16, 1 to 5 p.m. CT

PEGylated Hyaluronidase Increases Tumor Uptake of 89Zr-DFO-HuMab-5B1 (MVT-2163) in a CA19-9 Positive Hyaluronan-Accumulating Pancreatic Cancer Model. Abstract 3036. Tuesday, April 17, 8 a.m. to noon CT